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completing enteral nutrition in pediatric critically
ill patients (PEPaNIC trial): study protocol for a
randomized controlled trial
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Gonzalo Garcia Guerra3, Pieter J Wouters1, Ari Joffe3, Koen Joosten2, Dieter Mesotten1 and Greet Van den Berghe1*Abstract
Background: The state-of-the-art nutrition used for critically ill children is based essentially on expert opinion and
extrapolations from adult studies or on studies in non-critically ill children. In critically ill adults, withholding parenteral
nutrition (PN) during the first week in ICU improved outcome, as compared with early supplementation of insufficient
enteral nutrition (EN) with PN. We hypothesized that withholding PN in children early during critical illness reduces the
incidence of new infections and accelerates recovery.
Methods/Design: The Pediatric Early versus Late Parenteral Nutrition in Intensive Care Unit (PEPaNIC) study is an
investigator-initiated, international, multicenter, randomized controlled trial (RCT) in three tertiary referral pediatric
intensive care units (PICUs) in three countries on two continents. This study compares early versus late initiation of PN
when EN fails to reach preset caloric targets in critically ill children. In the early-PN (control, standard of care) group, PN
comprising glucose, lipids and amino acids is administered within the first days to reach the caloric target. In the
late-PN (intervention) group, PN completing EN is only initiated beyond PICU-day 7, when EN fails. For both study
groups, an early EN protocol is applied and micronutrients are administered intravenously. The primary assessor-blinded
outcome measures are the incidence of new infections during PICU-stay and the duration of intensive care dependency.
The sample size (n = 1,440, 720 per arm) was determined in order to detect a 5% absolute reduction in PICU infections,
with at least 80% 1-tailed power (70% 2-tailed) and an alpha error rate of 5%. Based on the actual incidence of new
PICU infections in the control group, the required sample size was confirmed at the time of an a priori- planned
interim-analysis focusing on the incidence of new infections in the control group only.
Discussion: Clinical evidence in favor of early administration of PN in critically ill children is currently lacking, despite
potential benefit but also known side effects. This large international RCT will help physicians to gain more insight in
the clinical effects of omitting PN during the first week of critical illness in children.
Trial registration: ClinicalTrials.gov: NCT01536275 on 16 February 2012.
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Nutritional support for children in intensive care
The state-of-the-art nutrition used for critically ill children
is essentially based on expert opinion, small studies with
surrogate endpoints and extrapolations from adult studies
or from studies in healthy children outside the ICU. It is
widely accepted that in healthy children, nutrition not only
serves to maintain body tissues but also allows growth,
which is considered of particular importance during in-
fancy and adolescence [1,2]. In hospitalized children, espe-
cially in the young, the current European and American
guidelines for nutrition recommend early parenteral nutri-
tion (PN) to prevent/correct malnutrition and to sustain
appropriate growth when enteral nutrient (EN) supply is
insufficient [3,4]. Observational studies suggest that about
a quarter of children, most notably infants, admitted to
pediatric intensive care units (PICUs) develop a pro-
nounced caloric deficit [1]. The stores of energy, fat and
protein in children are limited, leaving children to rely on
muscle mass to provide necessary substrates for metabol-
ism. The energy deficit observed with acute critical illness
in children has been associated with adverse outcome [5].
Based hereon, it is current practice in PICUs to start PN
in the acute phase of critical illness to supplement insuffi-
cient EN with the intention to avoid underfeeding [3,4].
However, overfeeding may also be harmful [6-9]. It is diffi-
cult to administer the correct amount of nutrition, avoid-
ing overfeeding as well as underfeeding.
Varying nutritional guidelines and clinical practices
It is currently advised to assess energy expenditure con-
sidered to reflect energy requirements, through the use
of indirect calorimetry during the course of critical ill-
ness and to use this technique for determining individu-
alized targets to guide nutritional therapy [10]. However,
a European survey conducted in 2004 showed that only
17% of the PICUs use this technique [11] and the tech-
nique itself has not been well standardized [12,13]. In
the most critically ill, major caveats are present, such as
respiratory support with more than 40% oxygen and the
use of uncuffed tubes resulting in unpredictable mea-
sures. The use of standard equations to predict energy
expenditure and/or requirements also carries the risk of
overfeeding and underfeeding [14-16].
Experts worldwide agree that there are insufficient data
to make evidence-based recommendations for the optimal
target of caloric intake in critically ill children and for the
optimal time after onset of critical illness by which this
target should be reached. The lack of widely accepted
caloric targets for critically ill children results in nutri-
tional strategies that vary substantially across centers. The
current European and American guidelines for nutrition
in hospitalized children recommend PN to prevent or cor-
rect malnutrition and to sustain appropriate growth whenEN supply is insufficient [10,17]. Most guidelines advise
doing this early so that the recommended daily allowances
for children are reached on day 2 or 3 after PICU admis-
sion. These recommendations are based on evidence from
cohort studies without a control group, case series or ex-
pert opinion (Grade D level).
The ongoing controversy on optimal amount, compos-
ition and timing of administration of PN in critically ill
children may in fact conceal the fact that there is no
hard evidence for any use of PN in critically ill children.
Supported by the results of a Cochrane systematic re-
view, Joffe et al. concluded that randomized trials inves-
tigating the role of intravenous nutritional support
during the first week of critical illness in children should
be performed and should include a control arm in which
no nutritional support is administered or hypocaloric
goals (below basal metabolic rate) for nutritional support
are used [18].
Rationale of the study and study hypothesis
A recent randomized controlled trial (RCT) in critically
ill adults [19] showed that the early provision of PN
worsened rather than improved outcomes as compared
with withholding PN and thus tolerating a substantial
caloric deficit up to 1 week in ICU. Also, other studies
did not show clinical benefit of early PN in adult ICU
patients [20,21]. Hitherto, no well-designed RCT has
been performed in critically ill children. The aim of the
PEPaNIC trial (the acronym stands for Pediatric version
of the effect of Early Parenteral Nutrition to complete
insufficient enteral nutrition in ICU patients) is to inves-
tigate whether a strategy of withholding PN during the
first 7 days in the PICU (late PN) provides clinical bene-
fit over the current practice of early PN in critically ill
children. We hypothesize that withholding PN for 1
week in the PICU reduces new infections and shortens
the duration of PICU-stay.
This hypothesis is currently being tested in a multicenter
superiority RCT performed in three large, tertiary referral
PICUs (University Hospitals Leuven, Leuven, Belgium;
Erasmus Medical Center, Sophia Children’s Hospital,
Rotterdam, The Netherlands; Stollery Children’s Hospital,
Edmonton, AB, Canada). The centers were invited to par-
ticipate based on a self-declared routine use of early PN in
the PICU. It was anticipated that this routine use of early
PN differs among centers. This was considered to be an
asset as it contributes to the external validity of the
PEPaNIC trial.
Methods/Design
Ethical approval
The study protocol and (deferred) informed consent
forms were approved by the institutional ethical review
boards in Leuven, Belgium (ML8052 Amend-ID0005),
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Edmonton, AB, Canada (Pro00038098). Informed consent
is given in writing by the parents or the legal guardians,
confirmed by the child when older than 7 years, after pro-
viding all information orally in plain language and in writ-
ing. For planned admissions, informed consent is obtained
prior to surgery/procedure. For unplanned admissions, in-
formed consent is obtained within 24 hours after admis-
sion on the PICU (deferred informed consent as the
nutritional therapy should be initiated from PICU admis-
sion onward).
Patients’ eligibility - Inclusion criteria
Upon admission to the participating PICUs, all critically
ill children are screened for nutritional risk and eligibil-
ity for inclusion in the PEPaNIC clinical study [22]. All
non-eligible patients, identified by the local investigators,
are logged.
Critically ill children, newborn to 17 years (inclusive
or exclusive depending on the local definition of a
pediatric patient) old, with a STRONGkids (Nutritional
risk score) score of 2 points or more and who are likely
to stay in the PICU for more than 24 hours, are eligible
for inclusion [22].
Exclusion criteria
Patients fulfilling one or more of the following criteria
are excluded:
 STRONGkids score lower than 2 on PICU
admission [22]
 Not critically ill (for example, anticipated oral intake
within 24 hours)
 Non-pediatric patients (aged 17 or older, compare
with above)
 Premature newborns (<37 weeks gestational age
upon admission in the PICU)
 ‘Do not resuscitate’ code at the time of PICU
admission
 Expected death within 12 hours
 Readmission to PICU after already having been
randomized
 Enrollment in another intervention trial
 Transfer from another PICU or neonatal ICU after a
stay of more than 7 days
 Ketoacidotic or hyperosmolar coma
 Inborn metabolic diseases requiring specific diet
 Short bowel syndrome or other conditions requiring
PN for more than 7 days prior to PICU admission
Data collection at study entry
At baseline, data on demographic (age, gender, race/
ethnicity, (pre-)admission bodyweight and height) and
clinical characteristics of the patients are obtained. For allpatients, severity of illness scores are calculated such as
the PEdiatric Logistic Organ Dysfunction PELOD score
and, for cardiac surgery patients, the Risk-Adjustment in
Congenital Heart Surgery or RACHS score. The Pediatric
RISk of Mortality (PRISM) score cannot be used for this
study as the nutritional management is expected to affect
the highest blood glucose concentration during the first
24 hours. In addition, co-morbidities prior to admission
are noted. These comprise, among others, the presence of
a genetic syndrome, gestational age at birth, presence/
history of cancer, diabetes mellitus, kidney failure and
infection upon admission.
Randomized treatment allocation
Randomization procedure
Randomization to early PN or late PN in a 1:1 ratio, is
performed centrally (KU Leuven, Belgium) by use of a
dedicated computerized system, accessible in all centers
around the clock, 7 days a week. The computer algorithm
allocates every consecutive, eligible patient per center to
one of the two treatment arms in a blinded fashion by use
of permuted blocks per diagnostic stratum to create paral-
lel groups. The block size is unknown to bedside physi-
cians, nurses and members of the research team. Patients
are stratified per study site according to age groups (<1
year and ≥ 1 year) and the following primary diagnostic
categories on admission:
I. Medical-PICU admissions (infectious or non-
infectious): (a) neurological (b) other.
II. Surgical-PICU admissions (elective or emergency)
according to referral discipline (a) cardiac surgery
(b) other.
Treatment allocation and blinding
Concealed allocation to the randomized treatment was re-
alized by use of the computerized randomization system
described above. It was considered not feasible to blind
treating physicians and patients for the allocated treatment
during the time window of the randomized intervention.
After discharge to the normal ward, all treating physicians
are unaware of the randomized treatment allocation. All
outcome assessors and investigators not directly involved
in the patients care, such as statisticians, infectious disease
specialists and laboratory personnel, are fully blinded to
treatment allocation.
Common strategy for early EN in both study arms
The initiation and increase of EN, and the use of gastro-
prokinetics are prescribed in the standing orders for EN
in each center. Both groups receive micronutrients (trace
elements, minerals and vitamins) intravenously from day
2 onwards until the amount of EN given reaches 80% of
the caloric target.
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Patients randomized to the early-PN strategy (standard
of care or control group) receive this type of nutrition
according to current management in each of the partici-
pating centers, which were recruited based on a routine
use of early PN. For patients randomized to the late-PN
group (intervention group), all PN is withheld during
the first week in the PICU. The international setting of
the trial brings some variation in the control group (see
study rationale and hypothesis), while the intervention
group is strictly standardized (‘no PN during the first
week in PICU’).
Standard of care or control group: early-PN
In the Leuven (BE) PICU, patients randomized to the
early-PN group receive a mixture of glucose 30% and
Vaminolact® (Fresenius, Uppsala, Sweden) in equal
amounts upon admission to PICU, comprising 150 mg/ml
glucose and 4.7 mg/ml nitrogen. For patients who require
fluid restriction, total fluid intake is 50 ml/m2/h on days 1
and 2 (the day after admission and further referred to as
day 2), and 60 ml/m2/h on day 3. Patients not requiring
fluid restriction receive 100 ml/kg/day for the first 10 kg
bodyweight, 50 ml/kg for the next 10 kg, and 20 ml/kg for
the bodyweight over 20 kg, to be reached within 3 days.
For all patients on intravenous (IV) nutrition, and within
the fluid limitation described above, lipids (SMOFlipid®
(20 g/100 ml), Fresenius, Uppsala, Sweden) are added
from the second morning after admission, initially at a
dose of 1.5 g/kg/day, increasing to a maximum of 3 g/kg/
day, depending on the age. On the third morning after ad-
mission, pharmacy-prepared PN preparations are pre-
scribed, unless adequate enteral nutritional intake is
expected. PN preparations contain a mixture of glucose
50% and SMOFlipid® covering respectively 60 to 70% and
40 to 30% of calculated energy target and a 1.5 to 2.5 g/kg
protein intake, according to age, by Vaminolact®. If the
body weight is above 5 kg, Vaminolact® is replaced by
Vamin 18® (Fresenius, Uppsala, Sweden). Any enterally-
delivered energy is taken into account twice daily to re-
duce the energy delivered by PN. When EN covers 80% of
optimal calculated caloric needs, PN is stopped. When the
patient starts to take oral nutrition, the PN and/or EN is
reduced and eventually stopped. Whenever enteral or oral
intake falls below 50% of calculated caloric needs, the PN
is restarted.
In the Rotterdam (NL) PICU, patients randomized to
the ‘early-PN’ group receive a continuous glucose infu-
sion upon admission to PICU (<30 kg; 4 to 6 mg/kg/
min, > 30 kg; 2 to 4 mg/kg/min). From day 2 onwards
the glucose intake is increased for all children on IV nu-
trition to 8.3 mg/kg/min (5 to 10 kg), 6.9 mg/kg/min (10
to 30 kg) or 4 mg/kg/min (>30 kg). Primene® (Baxter,
Kobaltweg 49, 3542 CE Utrecht) (5.5 to 5.7 mg/mlnitrogen) is added from day 2 onward at 25 ml/kg/day
(<10 kg) or 20 ml/kg/day (10 to 30 kg). From day 2
onwards, Intralipid® (Baxter, Kobaltweg 49, 3542 CE
Utrecht) is added initially at a dose of 10 ml/kg/day (<10
kg) or 7.5 ml/kg/day (10 to 30 kg), increasing to 20 or
15 ml/kg/day respectively. For patients who require fluid
restriction, intake is adjusted accordingly. Children > 30
kg on IV nutrition receive from day 2 onwards Olimel
N5 (Baxter, 5.2 mg/ml nitrogen, 115 mg/ml glucose)
when central lines are in place or Olimel N4 (Baxter, 4.0
mg/ml nitrogen, 75 mg/ml glucose) when only periph-
eral lines are in place; the dose is 48 ml/kg/day. Any
enterally-delivered energy is assessed twice daily and the
energy delivered by PN is reduced accordingly. Energy
goals for enteral nutrition are based on the body weight-
based Schofield equation [23] (first day of admission)
and on the Recommended Dietary Allowances (RDA,
Dutch Health Council) for the subsequent length of stay
(Dietary Reference Intake: energy, protein and digestible
carbohydrates, 2001, Health Council of the Netherlands:
The Hague). Energy goals and composition of parenteral
nutrition are based on the European Society of Pediatric
Gastroenterology, Hepatology and Nutrition (ESPGHAN)
guidelines [4]. When EN covers 80% of calculated caloric
needs, PN is stopped. When the patient starts with oral
nutrition, PN and/or EN is reduced and eventually
stopped. Whenever enteral or oral intake falls below 50%
of calculated caloric needs, PN is restarted.
In the Edmonton (CA) PICU, the patient’s energy ex-
penditure is assessed upon admission by a registered
dietitian when possible. Nutritional support is initiated as
soon as possible, with the goal to match energy expend-
iture (measured or estimated resting energy expenditure
of the child). The urgency of initiation of nutrition support
is dependent on nutritional risk prior to admission, disease
state and age. If indirect calorimetry cannot be done, 65%
of basal metabolic rate is used Food and Agriculture
Organization-World Health Organization (FAO-WHO) to
determine caloric requirement. This number is adjusted
daily by the dietitian based on the acute phase response
and clinical picture of the child. If nutritional require-
ments cannot be met enterally, PN is added to achieve cal-
oric target. On admission to PICU, patients receive a
glucose infusion of approximately 3 to 4 mg/kg/minute
taking into account the total fluid prescribed by medical
staff. At that time EN is initiated when possible. On the
morning of day 2, if the patient is not already on full en-
teral feeding, 20% IV lipids are initiated at 0.5 g/kg/day.
On the morning of day 3, if the patient is not already on
full enteral feeding, lipid infusion is increased to 1 g/kg/
day and a solution of amino acids and concentrated glu-
cose is added. The caloric goal is Basal Metabolic Rate
when the patient is intubated and Total Energy Expend-
iture when the patient has been extubated.
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In the 3 centers, patients randomized to the late-PN
group receive a mixture of glucose 5% and NaCl 0.9% at,
respectively, 60% and 40% of the total flow rate that is
required to obtain optimal hydration, as prescribed by
the attending physician, taking into account the volume
of EN that is being delivered. No other forms of PN
(lipid or protein infusions) are administered. When the
amount of EN that is administered still covers less than
80% of the calculated targets after 1 week in the PICU,
supplemental PN is initiated on day 8 according to the
current PN protocols in each center.
The medical and nursing staff of the PICU were all in-
formed and trained extensively during regular meetings
before the start of the trial and were familiarized with
the protocol. In order to optimize protocol compliance,
the protocol was programmed in the patient data man-
agement system (PDMS). The use of this program was
explained to every nurse, trainee and resident on the
PICU and was always supervised by the senior staff.
Adherence to the protocol in Leuven and Rotterdam
was guaranteed by using a PDMS guided system and by
careful follow-up by study nurses. In Edmonton, a paper
protocol was used and adherence checked by an inde-
pendent study nurse and physician.
Criteria for stopping the study intervention
When in the intervention arm (late-PN group), blood glu-
cose concentration falls spontaneously (without exogen-
ous insulin) below 50 mg/dl, the standard infusion of
glucose 5% is switched to 10% glucose until blood glucose
concentration is higher than 80 mg/dl and stable. There-
after, the infusion of glucose 10% is stopped again and
switched back to glucose 5%.
Blood glucose management
In Leuven, patients in both study groups receive con-
tinuous insulin infusion to target blood glucose levels of
50 to 80 mg/dl when aged < 1 year and 70 to 100 mg/dl
when aged ≥ 1 year. Blood glucose and potassium are
monitored systematically every 1 to 4 hours on the blood
gas analyzer (ABL Radiometer, Copenhagen, Denmark)
using undiluted arterial blood samples drawn via a VAMP®
system (Edwards Lifescience Pontbeekstraat 4 1702 Groot-
Bijgaarden), Edwards Lifescience Pontbeekstraat 4 1702
Groot-Bijgaarden [24] and insulin infusion is adjusted
when needed.
In Rotterdam, patients in all age groups receive con-
tinuous insulin infusion using a step-wise nurse-driven
glucose control protocol to target blood glucose levels of
72 to 145 mg/dl, except for patients with traumatic brain
injury for whom the target is set at 108 to 145 mg/dl
[25]. Blood glucose and potassium are monitored sys-
tematically every 1 to 3 hours on the blood gas analyzer(ABL 625; Radiometer, Copenhagen, Denmark) using ar-
terial or capillary blood samples.
In Edmonton, patients in all age groups receive continu-
ous insulin infusion at the discretion of the attending
physician when blood glucose levels exceed 180 mg/dl.
The attending physician sets the lower target range limit.
Other procedures and guidelines
Other medical treatments are not described by the study
protocol. Patients are weaned from the ventilator and
from hemodynamic support according to standardized
guidelines used in each participating PICU. End-of-life
decisions, when further intensive care is considered to
be futile, are taken in consensus by senior PICU physi-
cians and the referring specialist.
Handling of re-admissions to the PICU
Patients who are readmitted to the PICU after a partici-
pation in PEPaNIC are not eligible for reinclusion. Pa-
tients who are readmitted to the PICU within 48 hours
of discharge and who are still within the 7 days’ time
window of the initial randomization receive the nutrition
strategy they were randomly assigned to during the ini-
tial PICU admission. Patients readmitted more than 48
hours after PICU discharge will be fed at the discretion
of the attending physician (standard care).
Outcome measures
Primary endpoints
The two primary endpoints of this RCT are: (i) the inci-
dence of new infections during PICU- stay and (ii) the
duration of PICU dependency. The latter will be re-
ported as the crude number of PICU-stay days and as
the time to live discharge from PICU, to account for
mortality as a competing risk.
Also, the proportion of patients from the intention-to-
treat population who stayed 8 days or more in PICU will
be reported. This is not only reflecting the proportion of
prolonged critically ill patients but also examines effects
of the randomized intervention beyond the time window
of the randomized intervention in PICU.
The incidence of new infections for all patients in the
three centers will be scored in consensus by the same two
assessors (infectious disease specialists), who are blinded
for treatment allocation. This assessment is based on an a
priori-drafted protocol [19], which makes use of pre-
scribed antibiotics and clinical infection and inflammation
data.
As the timing of PICU discharge to a regular ward
may be affected by the availability of beds on regular
wards, which could induce bias, we a priori decided to
analyze ‘time to discharge from PICU’ as ‘time to ready
for discharge from PICU’. A patient is considered ‘ready
for discharge’ as soon as all clinical conditions for PICU
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risk of, vital organ support).
Secondary safety endpoints
Secondary safety endpoints comprise: (i) death during
PICU-stay and during the time window of the random-
ized intervention (up to day 8), (ii) the proportion of pa-
tients with at least 1 episode of severe hypoglycemia
(<40 mg/dl), (iii) in-hospital mortality and (iv) 90-day
mortality. As a specific Serious Adverse Event (SAE),
hypoglycemia resistant to bolus administration of glu-
cose during the time window of the randomized inter-
vention will be reported for both groups.
Secondary efficacy endpoints
1. Time to (live) discharge from hospital and duration
of hospital stay, for both the index hospitalization
and total hospitalization including stay in the
referred hospital.
2. Time to final (live) weaning from mechanical
respiratory support and duration of mechanical
ventilation.
3. Kidney failure. Proportion of patients in need for
renal replacement therapy (RRT) during PICU-stay
and the duration of RRT (for those patients requiring
RRT). Also, the further analysis of the maximum and
daily serum level of creatinine and urea during the
intervention window and during PICU-stay will be
reported. Other plasma and urine markers of kidney
function will be investigated.
4. Need for pharmacological or mechanical
hemodynamic support during PICU-stay and
duration of such need. In addition, time to final (live)
weaning from all pharmacological or mechanical
hemodynamic support in PICU will be analyzed.
5. Number of readmissions to the PICU. The
proportion of patients readmitted within 48 hours
after discharge will be recorded. Also the proportion
of patients readmitted to the PICU beyond 48 hours
during their index hospital stay will be reported, as
these patients will have been excluded from
treatment allocation and will receive standard care.
6. Liver dysfunction. Markers of liver function will be
measured and proportion of patients with abnormal
tests will be compared.
7. Inflammation. Effect of the intervention on
inflammation will be analyzed by comparing markers
of inflammation. Both peak values and time courses
will be analyzed.
8. Duration of antibiotic treatment. The duration of
antibiotic treatment (whenever given) within the
intervention window and during the PICU-stay will
be compared between the groups.9. Nutrition delivered during PICU-stay. The
macronutrients and calories administered during the
intervention window and thereafter during PICU-
stay will be compared between the treatment groups.
Total amount of macronutrients, as well as the
amounts administered parenterally and enterally, will
be reported.
10. Structural and functional differences in muscle tissue
during PICU-stay. By ultrasonography, skeletal
muscle thickness of the quadriceps, as a marker of
muscle wasting, will be reported in a subset of
patients. In addition, handgrip strength will be
measured in a subset of patients older than 6 years.
11. Intolerance to enteral feeding during PICU-stay.
Markers of tolerance to enteral feeding will be
determined in a subset of patients. Markers in blood,
stool and buccal swab samples will be investigated.
Further pre-planned studies (execution depending on
further funding), of which the detailed protocols and the
methods for statistical analysis will be reported separ-
ately, are here listed below:
1. Direct healthcare-related costs. Total, direct
healthcare costs during index PICU-stay will be
compared between the treatment groups [26].
2. Mechanistic studies. Explanations of any observed
effects of delayed administration of PN as compared
with standard of care will be assessed. These will
comprise, among others, metabolic, endocrine,
inflammation and (epi)genetic analyses, the
investigation of the role of severity of illness, the use
of indirect calorimetry, the type of blood glucose
management, and post-randomization factors such
as type and dose of administered macronutrients,
and disease evolution [27].
3. Long-term follow-up. This will include
developmental and neurocognitive assessments,
metabolic, endocrine, inflammation and (epi)genetic
studies, with a healthy matched control group
investigated over time in parallel.
Data collection following recruitment
All systemically applied medications received by the pa-
tients during the stay in PICU are registered. Every day
the quantities of kilocalories, carbohydrates, lipids and
proteins delivered by either PN or EN are calculated and
entered into the electronic Case Record Form (eCRF).
The need for and the number of days of mechanical ven-
tilatory support, of mechanical and pharmacological
hemodynamic support, of renal replacement therapies,
days on antibiotics and days requiring a central line are
recorded. Blood, urine, buccal mucosal swabs and hair
samples are taken upon PICU admission and during
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lected on ice when required) and immediately stored (at
room temperature or at −20°C/−80°C as appropriate) for
future measurements. Analyses on blood and urine for
the primary clinical analyses include routine chemistry,
hematology, and markers of inflammation. Further meta-
bolic, endocrine, inflammatory and (epi)genetic measure-
ments on stored samples in the context of mechanistic
analyses are planned. For mechanistic and exploratory
studies, ultrasound evaluation of the skeletal muscle, in
combination with muscle strength measurements will be
performed in a subset of patients [28-30]. Quality of life
on admission and after 4 to 6 months is recorded through
a validated, semi-structured questionnaire, filled out by
the parents, which is repeated at 2 and 4 years after enroll-
ment in the PEPaNIC trial.
Data handling and record keeping
Data are collected electronically in an anonymized eCRF,
unambiguously linked to the source file. Data are manu-
ally transferred and checked for accuracy into the eCRF
by the clinical research assistants’ team on a daily basis.
Extensive range and consistency checks are performed
by the study monitor. All original records, such as con-
sent forms, eCRFs and relevant correspondence, will be
archived at the participating centers, according to the
local regulations. Vital status at 90 days (and at later
follow-up times) will be recorded for all patients, by the
National Death Registries. When this information is not
available, vital status will be checked through the hos-
pital information system or the regional network of pedi-
atricians and general practitioners.
All data are stored anonymously. Investigators in-
volved in the trial do not have direct access to the data-
base. In addition, the study monitor has logged the use
of the database. After the trial, the study monitor will
store all data in a secured file that is only accessible by
the study monitor himself.
Trial organization
The sponsor (KU Leuven) provides direct access to the
eCRF, the source data and the study master file for mon-
itoring, for review by the independent ethics committee
and regulatory inspection. The sponsor established an
independent data safety monitoring board (DSMB). The
sponsor appointed one monitor. The monitor verifies
that the trial is performed in accordance to the protocol
as described in the European Medicine Agency’s ‘Note
for guidance on good clinical practice CPMP/ICH/135/
95.’ as well as the Declaration of Helsinki. Monitoring
is performed and reported according to the sponsor’s
standard operating procedures. The clinical research
team guarantees a daily follow-up of patient screening
and inclusion, availability of requested clinical data inthe clinical patient files and protocol compliance. Non-
compliance to the protocol and other questions or prob-
lems are reported to the study monitor and discussed
with the principal investigators and trial steering com-
mittee. SAEs are reported to the study sponsor and, if
needed, to the local ethics committee. The study moni-
tor regularly provides the sponsor and the DSMB with
reports on inclusions and SAEs. Regular meetings are
organized with principal investigators and clinical re-
search teams to discuss the daily progression of the
PEPaNIC trial.
The protocol has been instructed in each hospital to
all clinical medical and nursing staff through frequent
teaching sessions and clinical feedback rounds. The
protocol decision support is integrated into the PICU
PDMS in Leuven and Rotterdam, facilitating the pre-
scription of the exact amounts of PN and EN according
to protocol and clinical evolution.
In order to achieve adequate participant enrollment to
reach target sample size, regular meetings and site visits
take place every 3 months together with the Rotterdam
team and via teleconferences with the Edmonton team.
Regular data auditing is done by the administrative trial
team, the DSMB and by the central independent audit
procedure in place at the University Hospital of Leuven in
compliance with the European Trials Directives.
Statistical analysis plan
One Consolidated Standards of Reporting Trials
(CONSORT) diagram will be reported.
Protocol compliance will be documented by comparing
the actual amounts of PN and EN during the interven-
tion window and this will be reported as absolute num-
bers of calories and weight units.
For the primary and secondary endpoints taking place
during PICU-stay all data will be available. In case of re-
quest for discontinuation of the study intervention by pa-
tients, parents or legal guardians, this will be respected,
but all data will be analyzed. In case of consent with-
drawal, the parents will be asked whether the data can be
used for analysis. In case this would not be allowed, all
data of that patient will be removed from the database,
and this will be reported in the CONSORT diagram. At all
time, the intention-to-treat principle will be respected and
reported. No data imputation will be undertaken for any
of the primary or secondary outcomes.
Variables will be summarized as frequencies and per-
centages, means and standard errors of the means, or
medians and interquartile ranges, as appropriate.
Results will be analyzed with the use of chi-square test-
ing, Student’s t-test or non-parametric testing (Wilcoxon
rank-sum test, Van der Waerden test or Median test), as
appropriate. Kaplan-Meier plots will be used to document
time-to-event effects, and the time-to-event effect size will
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lysis. All time-to-event analyses will also be performed on
data censored at 90 days. As death is a competing risk for
duration of care outcomes, non-survivors will be censored
beyond the longest duration of such care required for sur-
vivors [19]. All outcomes will be analyzed both with and
without adjustment for baseline risk factors, including the
diagnostic and age groups, severity of illness, severity of
nutritional risk and center. The latter is considered neces-
sary to account for the differences among centers in nutri-
tion given to the control group and the variation in blood
glucose control targets. For these analyses, P-values will be
considered significant when at or below 0.05 without cor-
rection for multiple comparisons. To assess whether any
eventual impact of the intervention on the primary end-
points is affected by the baseline risk factor subgroups,
interaction P-values will be calculated (logistic regression
or Cox proportional hazard analysis) with a threshold for
significance of interaction set at a P-value of < 0.1. All ana-
lyses will be conducted on an intention-to-treat basis.
Sample size calculation and interim analyses
In the design phase of the PEPaNIC trial, and based on
the previous adult EPaNIC trial results, the sample size
(N = 1,440, 720 patients per arm) was determined in
order to detect a reduction in the incidence of new in-
fections during PICU-stay from 20 to 15% (Absolute
Risk Reduction 5%), with at least 80% 1-tailed power
and at least 70% 2-tailed power and at an alpha error of
5%. With this sample size, the trial can also detect a
major safety issue, such as a doubling of the PICU mor-
tality rate from 4% (the baseline mortality in the Leuven
center) to 8% with a statistical power of 89% in a 2-sided
test with an alpha error of 5%. This sample size will also
allow to detect a reduction in mean duration of stay in
PICU of 1 day with at least 90% power (2-tailed) and
95% certainty.
Two interim analyses of the safety endpoints (except
90-day mortality) only were planned (after inclusion of
480 upon specific request of the DSMB, and after inclu-
sion of 50% of the study population). It was a priori de-
cided to determine the actual incidence of new infections
during PICU-stay in the 3 centers, as this was not known
exactly for each of the participating centers prior to trial
initiation. In order to allow statistical repowering and to
judge the necessity of inclusion of more trial sites, the as-
sessment of incidence of new infections during PICU-stay
in the control group took place after inclusion of 750 pa-
tients. Based on this actual incidence of new PICU infec-
tions in the control group, the hypothesized absolute risk
reduction of 5% and an alpha error rate of 5%, the sample
size of 1,440 patients (720 patients in each arm) was found
sufficiently large to yield a statistical power of 77% 2-sided
and of 85% 1-sided. As these interim analyses did notassess any of the efficacy endpoints, no adjustments of the
P-values are needed.
Discussion
The clinical evidence for the administration of PN in crit-
ically ill children is missing [18]. Thousands of children are
annually exposed to this non-evidence-based treatment,
which is assumed to result in faster recovery (benefit). This
large international RCT will help PICU physicians to ob-
tain more insight into the possibility of the omission of PN
during the first week of critical illness. A significant differ-
ence in the safety and/or efficacy endpoints will provide
important evidence for optimizing clinical patient care.
Also a neutral result will provide important insight, as this
would mean that clinicians can safely withhold PN in all
comparable patients during the first week of ICU stay,
which would have an impact on healthcare spending in the
PICU.
Trial status
The study was initiated as planned on 18 June 2012. At
the time of the safety interim analyses (after 480 and 750
study patients discharged from PICU), the DSMB ad-
vised the continuation of the trial and ratified the initial
sample size of 1,440 patients as adequate to test the hy-
pothesis. On 1 December 2014, 1,130 patients have been
included into the PEPaNIC trial. Recruitment of the last
patient is expected for October 2015.
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